作者
Remy B Verheijen, Huixin Yu, Jan HM Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin DR Huitema
发表日期
2017/11
来源
Clinical Pharmacology & Therapeutics
卷号
102
期号
5
页码范围
765-776
简介
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
学术搜索中的文章
RB Verheijen, H Yu, JHM Schellens, JH Beijnen… - Clinical Pharmacology & Therapeutics, 2017